Navigation Links
Chiasma to Present at the UBS Global Life Sciences Conference
Date:9/14/2011

NEW YORK and JERUSALEM, Sept. 14, 2011 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, announced that Fredric Price, Chiasma's Chairman & CEO, will present an overview of the Company at the UBS Global Life Sciences Conference at the Grand Hyatt, New York, New York, on Monday, September 19, 2011 at 1:30 PM.

Chiasma's investigational new drug Octreolin™ is an oral form of octreotide acetate being developed first for the oral treatment of acromegaly, a hormonal disorder that results from an excess of growth hormone.  The Company successfully completed 4 clinical studies with Octreolin in healthy volunteers, having established a pharmacokinetics profile similar to that of subcutaneously injected octreotide acetate.  In addition, Octreolin demonstrated the ability to reduce growth hormone.  No serious adverse safety events were reported in any of the studies.  A trial in patients will commence in October 2011.  Chiasma intends to file an NDA using the 505(b)(2) regulatory pathway in the US and its EMA equivalent, the Hybrid Application in Europe.

Octreolin is also being developed as a chronic treatment for patients with Portal Hypertension (PHT); a Phase 2 proof of concept trial for this new orphan indication (no drugs are approved for PHT in the US) was initiated in September 2011.  The Company has a pipeline of products that are currently in preclinical development including one in renal disease that will enter the clinic in mid-2012.

About Chiasma

Chiasma develops new drug products based on its proprietary Transient Permeability Enhancer (TPE) technology, which enables oral delivery of macromolecules (up-to 20 kDa) and poorly-absorbed small molecules into the portal system and then to the systemic circulation.  The TPE technology not only enables their being converted from injectable to oral, but importantly can result in the development of new indications.

Chiasma is a Delaware corporation with a 100% owned Israeli subsidiary.  It is backed by MPM Capital, ARCH Venture Partners, F-2 Ventures and 7 Med Health Ventures.

Additional information can be found at:  www.ChiasmaPharma.com.

Forward-Looking Statements

This press release contains forward-looking statements about the business, goals and prospects of Chiasma, Inc., including, without limitation, statements about the development of drugs in the TPE system.  These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements.  Chiasma is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Chiasma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chiasmas Octreolin™ (Oral Octreotide) Shown to Inhibit Growth Hormone in Healthy Subjects
2. Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products
3. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Heska to Present at LD MICRO Invitational on September 22, 2011
6. Isis Pharmaceuticals to Present at the UBS Global Life Sciences Conference
7. BioMarin to Present at the UBS Global Life Sciences Conference
8. Henry Schein to Present at the CL King 9th Annual Best Ideas Conference 2011
9. PDL BioPharma to Present at Upcoming Investor Conferences
10. Pacira Pharmaceuticals, Inc. to Present at UBS Global Life Sciences Conference
11. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today ... December 31, 2015. The Company also filed its Quarterly Report ... 2016 with the Securities and Exchange Commission today. ... 2015 --> --> Net ... $2.6 million, or 95%, to $5.4 million from $2.8 million ...
(Date:2/11/2016)... , Feb. 11, 2016 Laboratory ... used in laboratories. These may range from microscope slides ... glassware is made from borosilicate glass because of its ... on the other hand, started gaining popularity over the ... easier to replace glass with plastic in several applications ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 12, 2016 , ... The Journal of ... from 0.416 in 2013. The SJR uses data taken from the Scopus database (Elsevier ... the number of citations received by the journal over a three year period and ...
(Date:2/11/2016)... ... 2016 , ... The president released a FY 2017 budget request on Tuesday ... of the cost burden to military beneficiaries. , MOAA’s president, retired Air Force ... as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We ...
(Date:2/11/2016)... ... 11, 2016 , ... Hall Integrative Health and Chiropractic, PC ... simultaneous grand openings in March. All seven practices are set to start accepting ... reversing diabetes possible? According to this 2011 CNN article it is possible: ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... women’s health, is pleased to announce the promotions of Allison Kelly to executive ... Steve Catone to executive vice president of North American capital sales, and Wendy ...
(Date:2/11/2016)... ... 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased ... Study for Plans and Purchasers.” Executives from Intel Corp. and Providence Health & ... health benefits program Connected Care, will discuss the challenges they faced (and how ...
Breaking Medicine News(10 mins):